Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis

BACKGROUND: Vorinostat, a histone deacetylase (HDAC) inhibitor, was investigated in combination with capecitabine plus cisplatin (XP) as a first-line chemotherapy for patients with unresectable or metastatic gastric cancer (GC). METHODS: Eligible patients received 400 mg vorinostat once daily on day...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Yoo, Changhoon, Ryu, Min-Hee, Na, Young-Soon, Ryoo, Baek-Yeol, Lee, Chae-Won, Kang, Yoon-Koo
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2016
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4891506/
https://ncbi.nlm.nih.gov/pubmed/27172248
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.125
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars